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The enantioselective hydration of electron-rich C=C bonds is a synthetic challenge, 
particularly for the sustainable production of fine chemicals. Biocatalytic alternatives are 
developing, yet current options face limitations to their industrial application. 
The enzyme Linalool Dehydratase-Isomerase (LDIase) enantioselectively adds water to 
myrcene in this way using a novel mechanism, further complemented by dehydration and 
isomerisation functions. This may not only bear a prospective biocatalytic tool for 
enantioselective hydration, but could also facilitate the manufacture of polymers from 
natural feedstocks. 
To enable the application of LDIase as an industrial biocatalyst, this work further explored 
this enzyme’s mechanistic details using structural studies. A 2.58 Å resolution structure of 
an LDIase mutant was obtained which gave an initial indicator of a covalent intermediate. 
An aerobic homologue was also investigated as a possible industrial alternative. 
A comprehensive understanding of this enzymatic hydration mechanism will allow rational 
engineering of LDIase to expand its substrate range, for the diverse production of highly 
valuable chemicals. By this method, we may reduce our reliance on non-renewable 
petrochemical sources and energy-intensive synthesis to produce natural chemicals of 
higher quality. 
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Introduction 
1.1. Enantioselective hydration 
1.1.1. Water, the reactant 
The hydration of alkenes is ubiquitous in nature, yet remains a laboured process for our own 
methods of chemical synthesis. Although the possession of lone pairs allows water to act as 
a nucleophile, its low electron density makes it a particularly weak one. This is exacerbated 
during water addition to electron-rich alkenes, where the reaction conditions can reduce 
water’s electronegativity by protonating it.[1] Additionally, as water is both solvent and 
nucleophile, hydrogen bonding between molecules contributes to water’s polar protic 
nature by reducing the availability of its lone pairs. Its excess as a solvent also leads to the 
position of equilibrium lying towards the starting material, which is less than ideal for 
producing industrially important chemicals.  These factors do water few favours in 
appearing as an attractive reactant. 
This being said, a reactant which is both exceptionally safe and in abundance on Earth is 
alluring, and many attempts have been made over the years to tap into the potential of 
hydration reactions. 
The most widely-used hydration reaction today in the chemical industry is for the 
production of ethanol. Aside from fermentation, this can be accomplished by hydrating 
petrochemical-derived ethylene in steam using a phosphoric acid-based catalyst at high 
temperatures and high pressure.[2] The mechanism of this electrophilic addition, which uses 
acid catalysis, provides some insight into the challenges for the addition of water to electron-
rich alkenes (Figure 1.1). 
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Figure 1.1 Scheme of industrial ethylene hydration using steam and a phosphoric acid catalyst. 
In this reaction, phosphoric acid acts as a Brønsted-Lowry acid, donating a proton to 
ethylene and forming a carbocation intermediate. Water carries out a nucleophilic attack of 
the protonated ethane, now a conjugate acid, to form an oxonium ion. In the final step this 
is deprotonated by the oxidised phosphoric acid to form ethanol and to regenerate the 
catalyst. 
Another example of water addition to an electron-rich alkene is the hydration of isobutylene 
to form tert-butyl alcohol. This reaction occurs similarly to that of ethylene hydration, with 
the difference of occurring in the liquid phase under high pressure and using an acidic cation 
exchange resin.[3] However, unlike ethylene, isobutylene is an asymmetric alkene and 
therefore the location of carbocation formation affects the location of water addition (Figure 
1.2). The Markovnikov Rule explains this issue; it states that the carbocation is most stable 
the more substituents it has. In practice, this means that hydrogen will be added to the 
carbon that is initially bound to the greatest number of hydrogens, and water will be added 
to the carbon which binds the fewest. 
Figure 1.2 Scheme demonstrating the Markovnikov Rule applied to isobutylene's carbocation 
intermediate of hydration. 
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Although both of these reactions show industrial applications of electron-rich alkene 
hydration, they are faced with a number of problems. The high temperatures and pressures 
required in these reactions increase costs, and this energy requirement coupled with the 
petrochemical source of the starting materials makes it environmentally unsustainable. 
Additionally, side reactions and dehydration of the product back to the starting material 
frequently occurs.[1] This is not only inefficient, but also reduces the purity of the desired 
chemical or requires additional workup steps. Although these processes are relatively 
straightforward for simple alcohols, they become much more difficult for more complex 
chemicals such as terpenes. 
1.1.2. Enantioselectivity 
Of all the problems described for industrial hydration, the most pressing is 
enantioselectivity. One of the ways in which chemicals increase in complexity is the 
possession of an asymmetric carbon, one bonded to four different groups. Compounds with 
these chiral centres exist as two enantiomers, (R)- or (S)-, which are mirrors of each other 
(Figure 1.3). 
Figure 1.3 The two enantiomeric assignments of linalool shown from a chiral-centric view, 
demonstrating CIP priority rules in blue. 
Although the difference between such enantiomers can appear small when drawn, their 
real-world differences are stark. Nature itself shows favouritism; sugars are mostly D and 
amino acids L. The reason for this homochirality is not fully understood, however theories 
include the preferential destruction of single enantiomers by nuclear decay, or simply 
random chance.[4]
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However, the relevance of enantiomers does not stop with their natural distribution. As 
nature shows favouritism in production, so does it in response; often only one enantiomer 
of a chemical will be physiologically active, but sometimes each enantiomer will induce 
contrasting effects. Scent is a good example of this, and our olfactory system can detect these 
subtle differences in chirality.[5] The flavour and fragrance industry is therefore particularly 
interested in scalable enantioselective synthesis. 
Drugs are another example of this, even though for many enantiopurity is inconsequential. 
Ibuprofen (painkiller), cetirizine (antihistamine) and salbutamol (asthma) have been sold as 
racemic mixtures, even if a single enantiomer is preferentially active.[6] The primary reason 
for choosing enantiopurity in these instances would be efficiency of production. Yet drugs 
with enantiomers possessing different activities can have profound effects, such as the 
developmental effects of racemic thalidomide.[7]
Chemical synthesis struggles to achieve the same enantioselectivity achieved by nature. For 
the hydration of alkenes, several synthetic chemical attempts have been made; Vanderwal & 
Jacobsen developed an aluminium salen catalyst,[8] while Hartmann et al. opted for silicon- 
and boron-based complexes.[9] Boersma et al. took a different route with a DNA-based 
catalyst.[10] Although successful at introducing chirality, these catalysts were only 
demonstrated on electron-deficient enones. On the other hand, Ying Yan Jiang’s group at 
the Chinese Academy of Sciences have used a wool-palladium complex to hydrate electron-
rich carbon-carbon double bonds.[11,12]
These studies show that although synthetic chemistry solutions for the hydration of carbon-
carbon double bonds do exist, they are applicable only to electron-deficient substrates or 
require rare metals and energy-intensive temperatures or pressures. Reactions of this kind 
are also frequently limited by low yields or poor enantiomeric excess. These factors make 
them a less than ideal solution to introducing chirality, and create an essential niche for 
catalysts which can enantioselectively hydrate electron-rich alkenes cheaply in an 
environmentally benign manner. 
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1.2. Biocatalysis 
1.2.1. Life’s catalyst 
Mirroring the chirality of nature, life has evolved enzymes that perform enantioselective 
catalysis. The shape of an enzyme’s active site precisely positions the substrate for specificity, 
while the location of catalytic amino acid residues controls selectivity.[13] This allows for 
chemo-, regio- and stereoselectivity, in addition to enantioselectivity. The precision with 
which enzymes control their reactions is necessary for ensuring side products are not 
formed, which can have potentially harmful physiological effects or undesired 
environmental consequences. Fortunately, these very properties also make enzymes an ideal 
tool for industry. 
1.2.2. Man’s biocatalyst 
Our use of enzymes predates synthetic chemistry, having been exploited for millennia 
through fermentation for the conversion of sugars to alcohol. As our understanding of 
enzymes and their mechanisms has progressed, we have begun to use this natural tool for 
increasingly more advanced chemistry. Not only do enzymes boast the aforementioned 
specificity and selectivity, but their preference for mild conditions makes them much more 
environmentally benign than conventional chemical catalysts.[14]
Biocatalysis for important industrial reactions has been steadily increasing in recent years. 
In the flavour and fragrance industry the use of single enantiomers creates more realistic 
tastes and scents, while enzymatic production fulfils customers’ increasing preference for 
natural products. In practice, the biotechnology companies Evolva and Oxford Biotrans have 
each developed an enzymatic technique for the manufacture of nootkatone, a chiral 
compound and principle contributor to grapefruit aroma (Figure 1.4).[15,16] Traditional 
methods of nootkatone extraction from grapefruit are expensive and difficult due to the 2.5 
× 10-4 % yield, however biocatalytic methods such as these provide a viable alternative which 
is being established for other flavour and fragrance chemicals. 
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Figure 1.4 Conversion of valencene to nootkatone, as catalysed by a cytochrome P450 enzyme. 
Biocatalysis is also being applied to produce enantiopure pharmaceuticals. Ketoreductases 
are now an established route for the synthesis of chiral intermediates for atorvastatin to 
lower cholesterol,[17] and transaminases for the antidiabetic drug sitagliptin (Figure 1.5).[18]
Complex drugs such as these often require multiple steps for their production, more of 
which now implement biocatalysts as the technology improves.[19]
Figure 1.5 Production of atorvastatin and sitagliptin precursors by biocatalysis, using either a 
ketone reductase or a transaminase respectively, introduces correct chiral centres to these drugs. 
These modern biocatalytic reactions use isolated enzymes, which offer advantages in organic 
solvent tolerance and simpler product retrieval over whole-cells.[20] However, synthetic 
biology methods can engineer pathways for enzymatic cascades in whole-cells; a landmark 
example is artemisinin precursor production in yeast using cytochrome P450s, pioneered by 
Jay Keasling’s group in collaboration with Amyris and Sanofi (Figure 1.6).[21–23]
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Figure 1.6 An engineered biosynthetic mevalonate pathway of S. cerevisiae is complemented by 
the oxidation activity of a cytochrome P450 enzyme to produce the precursor of the antimalarial 
drug artemisinin. 
As solutions to the formidable challenge of climate change become increasingly pressing, 
biocatalysis provides a potentially effective one. Its reduced environmental impact is not just 
important for reducing energy consumption and the reliance on toxic catalysts, but also by 
minimising our reliance on petrochemical sources. Many important polymers could only be 
made on an industrial scale from petroleum, but biocatalysis has facilitated production of 
partly bio-based polytrimethylene terephthalate (PTT) from dehydratase-fermented 1,3-
propanediol (Figure 1.7).[24–26]
Figure 1.7 1,3-Propanediol (PDO) is catalysed from corn-derived glucose by three enzymes 
engineered into E. coli, replacing traditional petrochemical sources. This Bio-PDO is used to 
manufacture the PTT product Sorona (Du Pont). 
As novel enzymes are discovered and their mechanisms fully understood, we can engineer 
biocatalysts to create affordable aromas, safe drugs and green materials. 
1.3. Hydratases 
Applying biocatalysis to alkene hydration provides another solution to the challenges of 
enantioselectivity faced by synthetic methods. There are currently a number of enzymes 
used industrially to accomplish this. 
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1.3.1. Fumarase 
Fumarase is an enzyme essential in the citric acid cycle for the conversion of fumarate to (S)-
malate, hydrating the central carbon-carbon double bond (Figure 1.8). This process 
contributes to the generation of the electron carrier NADH which is fed into the oxidative 
phosphorylation pathway to form ATP. 
Figure 1.8 Fumarase asymmetrically hydrates fumarate to (S)-malate in the citric acid cycle. 
Two types of active site exist for fumarases; Fe2+-dependent class I and cofactor-
independent class II. Class I fumarases (FumA and FumB) use a [4Fe-4S] iron-sulfur cluster, 
where the non-protein bound iron is postulated to ligate both water and one of the 
carboxylate groups of the fumarate. Rather than forming a carbocation intermediate, this 
mechanism uses a covalent intermediate. This way, it increases proximal interactions to 
perform an intramolecular reaction. Here the iron acts as a Lewis acid catalyst, facilitating 
the reaction by increasing the electronegativity of its ligated carboxylate oxygen. Catalytic 
amino acid residues then separately accept a proton from bound water, and donate a proton 
to the carbon double bond (Figure 1.9).[27–29]
Figure 1.9 Mechanism of fumarate hydration by the class I fumarase metalloenzymes. ‘X’ 
represents catalytic amino acids of the active site. 
Class II fumarases (FumC) are homotetramers with four active sites each situated between 
three subunits, and an additional allosteric binding site.[30] Unlike class I fumarases they do 
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not possess an iron-sulfur cluster, so must utilise a different mechanism for hydration. This 
is accomplished by acid-base catalysis, with a protonated amino acid residue acting as an acid 
and a deprotonated residue acting as a base. The basic residue activates water by 
redistributing electron density towards oxygen for addition, while the acidic residue donates 
a proton to the C3 carbanion (Figure 1.10). Which specific residues these are in fumarase is 
not fully known, however for fumarate hydration it is likely that the acid is serine and the 
base histidine.[31] Whether fumarate hydration or (S)-malate dehydration occurs depends 
on the protonation state of the amino acids.[32]
Figure 1.10 Mechanism of fumarate hydration by class II fumarase. 
The distinct mechanisms of enzymes which catalyse the same reaction raises the question of 
why this difference has evolved. It is suggested that the class I fumarases are utilised under 
anaerobic or microaerobic conditions, and class II is used in aerobic conditions where 
oxygen-sensitive metal cofactors would be inactivated.[33] This also applies to industry, 
where enantiopure (S)-malate is important for pharmaceuticals.[34] This has led to the use 
of class II fumarases in its production, for oxygen tolerance and stability at higher 
temperatures.[35]
1.3.2. Enoyl-CoA Hydratase 
Enoyl-CoA hydratase, also known as crotonase and the namesake of the same superfamily, 
catalyses the hydration of trans-2-enoyl-CoA to 3-hydroxyacyl-CoA as part of the β-
oxidation pathway (Figure 1.11). This process generates acetyl-CoA, which is supplied to the 
citric acid cycle of fumarase. The homohexameric protein is a dimer of trimers and has six 
active sites in total, each formed at the interface between two subunits.[36] The flexible active 
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site loop gives the enzyme a broad substrate spectrum, with chain lengths of trans-2-enoyl-
CoA from four to twenty carbon atoms.[37]
Figure 1.11 Hydration reaction catalysed by enoyl-CoA hydratase in the β-oxidation pathway. 
The proposed acid-base mechanism is likely to proceed by a carbanion intermediate, 
although a concerted transition state has also been suggested as a possibility.[38,39] Glutamate 
activates water for attack of the carbon-carbon double bond by the oxygen lone pair, 
forming the carbanion intermediate. This then abstracts the residual proton from glutamate 
to complete the reaction (Figure 1.12). 
Figure 1.12 Carbanion intermediate mechanism of enoyl-CoA hydratase, utilising a similar 
Michael addition to class II fumarase. 
The oxyanion hole is particularly important for stabilisation of the carbanion intermediate, 
specifically in this instance glycine and alanine residues.[40] This particular enoyl-CoA 
hydratase catalyses the (S)-specific hydration, interestingly others carry out the (R)-specific 
reaction instead.[41] Eukaryotes often carry out the enoyl-CoA reaction in multifunctional 
enzymes, which have 3-hydroxyacyl-CoA dehydrogenase activity at one terminal domain 
and enoyl-CoA hydratase activity at the other, dependent on the enzyme.[42–44]
Enoyl-CoA hydratases can be used industrially to make 3-hydroxybutyrate for biopolyesters 
such as poly[(R)-3-hydroxybutyrate].[45] Similarly, 3-hydroxyisobutyric acid can be 
produced in a multi-enzyme pathway as a precursor for methacrylic esters such as 
poly(methyl methacrylate), which is also known by the trade name Perspex.[46] Enoyl-CoA 
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hydratase can serve in the adipate degradation pathway to adipyl-CoA to make precursors 
of the drug aminocaproic acid and the synthetic fibre polymer polycaprolactam.[47] For non-
biocatalytic applications, enoyl-CoA is targeted by Henkel to reduce the unpleasant smell 
caused by 2-methylbutyric acid and isobutyric acid during the fermentation process for 
industrial detergent enzyme production.[48]
Although fumarase and enoyl-CoA are used industrially for carbon-carbon double bond 
hydration, their substrates are limited to enones using the Michael reaction. Although they 
provide a fascinating insight into the mechanism of hydration reactions, other enzymes will 
need to be explored to build biocatalytic tools for hydrating electron-rich alkenes. 
1.3.3. Oleate Hydratase 
Catalysing the hydration of the C18 monounsaturated ω-9 fatty acid oleic acid to (R)-10-
hydroxysteric acid (Figure 1.13), oleate hydratase was discovered in the soil bacterium 
Pseudomonas.[49] Structural studies on this enzyme have since caused a change in host name 
to Elizabethkingia meningoseptica and revealed a flavin-dependent monomeric enzyme.[50]
Figure 1.13 (R)-selective water addition to oleic acid by oleate hydratase. 
The mechanism employs acid-base catalysis, with amino acid residues glutamate and 
tyrosine playing a key role. The FAD cofactor is proposed to orient the substrate and 
stabilise the transition state. The glutamate residue activates the water similarly to 
mechanisms discussed previously, which in turn attacks the positive dipole of C10 at the re-
face. Finally, this carbon abstracts a proton from tyrosine (Figure 1.14).[51]
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Figure 1.14 Hydration mechanism of oleate hydratase. An FAD cofactor is utilised by the enzyme 
(not shown). 
The production of (R)-10-hydroxysteric acid using oleate hydratases is industrially applied 
by the flavour industry for the production of γ-dodecalactone, which contributes to the 
flavour of whiskey.[52–54]
1.3.4. Carotenoid 1,2-Hydratase 
Carotenoid hydratases have been discovered in two forms; CrtC from photosynthetic 
bacteria and CruF from a non-photosynthetic bacterium.[55] Both terminally hydrate long, 
highly unsaturated C40 hydrocarbon carotenes; CrtC catalyses lycopene to 1-HO-lycopene 
then 1,1’-(HO)2-lycopene (Figure 1.15), whilst CruF hydrates γ-carotene. 
Figure 1.15 The carotenoid 1,2-hydratase CrtC can hydrate each end of lycopene consecutively. 
No structure is available for this class of hydratase, though a mechanism has been suggested 
for CrtC using a homology model.[56] The proposed mechanism is by acid-base catalysis, 
with an aspartate residue acting as the acid, with its acidity enhanced by a neighbouring 
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histidine and bridged to tyrosine by a water molecule (supplementary online text).[56] The 
elucidation of a structure, ideally as a Michaelis complex, would shed light on this mystery. 
Although enzymes exist for the hydration of electron-rich carbon-carbon bonds, there are 
few which are well characterised. New enzymes with novel mechanisms are essential for the 
industrial implementation of this promising biocatalytic tool, such as for the production of 
monoterpenes. 
1.4. Terpenes 
Terpenes are unsaturated hydrocarbon derivatives of isoprene, their molecular building 
block. This class of natural organic compounds have strong aromas and are primarily 
released by plants for defence or cloud-seeding, and by some insects.[57] Humans best know 
them for their strong and pleasant aromas as natural essential oils, and are found in the 
majority of perfumes, cosmetics and personal care products. They have become a 
cornerstone of the fragrance industry, but are also rapidly becoming an essential source of 
new drugs such as artemisinin. 
Figure 1.16 The isoprene rule as demonstrated using myrcene. Individual isoprene units are 
coloured separately, with the isoprene backbones in bold. 
Terpenes exist in a variety of classes, based on the isoprene rule of (C5H8)n where n 
represents the number of isoprene units connected by a carbon-carbon bond (Figure 1.16). 
The isoprene rule can also be applied to compounds we often have different associations 
with; for example, Vitamin A is a terpene. Selected terpene classes are shown in Table 1.1. 
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Table 1.1 Representative terpene classes, displaying the number of isoprene units, the molecular 
formula, and notable examples. The monoterpenes also include linalool and geraniol. 
Class Isoprene units Molecular formula Examples 
Hemiterpenes 1 C5H8 Isoprene 
Monoterpenes 2 C10H16 Pinene, Limonene, Myrcene 
Sesquiterpenes 3 C15H24 Farnesol, Humulene 
Diterpenes 4 C20H32 Taxadiene 
Triterpenes 6 C30H48 Squalene 
Tetraterpenes 8 C40H64 Lycopene 
Polyterpenes n Natural rubber 
Monoterpenes are one such class, and are one of the most common terpenes used for their 
bright scents. Below we will discuss three of these monoterpenes; myrcene, geraniol, and 
linalool, and how they are currently industrially synthesised and employed. 
1.4.1. Myrcene 
Myrcene exists as two isomers, α-myrcene and β-myrcene; it is the latter which occurs 
naturally (Figure 1.17). β-myrcene is a colourless oil with a sharp herbal scent, and makes a 
considerable contribution to the aroma of hops.[58]
Figure 1.17 The two constitutional isomers of myrcene. Only β-myrcene exists in nature (bold). 
A strain of Rhodococcus erythropolis has been isolated from the soil of hop plants which 
catalyses β-myrcene to geraniol.[59] For the industrial production of myrcene, turpentine is 
used; a distillate of pine trees containing α- and β-pinene. The latter undergoes pyrolysis to 
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break the bicyclic ring, forming myrcene. Although theoretical yields could be as high as 
93.5%, the maximum reported yields are 85%.[60]
1.4.2. Geraniol 
Geraniol, or trans-3,7-dimethyl-2,6-octadien-1-ol, is widely used as a fragrance in many 
consumer products including soaps and perfumes (Figure 1.18). It carries a fresh, citrus scent 
and is a key constituent in the essential oils of rose, lemongrass and palmarosa.[61] Nerol is 
the cis-isomer of geraniol, with a similar yet distinct aroma. 
Figure 1.18 The cis-trans stereoisomers geraniol (trans) and nerol (cis). 
Fractional distillation of these essential oils yields high-purity natural geraniol, though 
industrial chemistry can produce it synthetically. This can include the selective 
hydrogenation of petrochemically-derived citral and distillation using ruthenium-iron or 
platinum-zinc oxide catalysts.[62,63] BASF is one such company which has purpose-built 
facilities to carry out this reaction on an industrial scale. 
1.4.3. Linalool 
Whereas myrcene exists as two constitutional isomers and geraniol has a configurational 
isomer, linalool is chiral at C3 and thus has two enantiomers; (S)-(+)-linalool and (R)-(-)-
linalool (Figure 1.19). By chemical nomenclature it is known as 3,7-dimethylocta-1,6-dien-
3-ol. 
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Figure 1.19 Enantiomers of linalool, with both found in nature. 
Unusually for a chiral compound, linalool is found in nature as both of its possible 
enantiomers. (R)-linalool is known as licareol and is described as having a woody, lavender-
like aroma. (S)-linalool, or coriandrol, gives a difference scent illustrated as sweet, floral and 
citrusy.[64]
This substantial difference in scent creates a problem for the flavour and fragrance industry, 
which widely uses linalool in 61-97% of household products and cosmetics.[65] Natural 
extraction provides control over this disparity, however yields are low.[66] Current methods 
for industrial production involve semisynthesis of pinene, or organic synthesis of 2-methyl-
2-hepten-6-one.[64]
However, this racemic linalool does not hold the desired aroma of a single enantiomer, and 
thus cannot evoke the same recognition of the scents we experience in our environment.[67]
Instead, they take on an artificial ‘chemical’ smell; undesirable for selling fragranced 
products. 
Approaching linalool synthesis as nature does may help alleviate this issue. Plants employ a 
variety of linalool synthases to make linalool enantioselectively, however for industrial 
application feedstock price and availability must be taken into account.[68] A practical 
alternative is utilising biotechnology for this purpose, such as microbial transformations, 
synthetic biology and biocatalysis.[69,70]
With the cost of natural product extraction of valuable terpenes remaining high while 
demand continues to increase, industry must rely on synthetics. However, this presents 
additional challenges in enantioselectivity. The use of modern biotechnological techniques 
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such as biocatalysis can solve both of these issues by creating ‘naturally’ formed products that 
are also enantiopure. 
1.5. Linalool Dehydratase-Isomerases 
1.5.1. C. defragrans Linalool Dehydratase-Isomerase (LDIase) 
Linalool Dehydratase-Isomerase, named LDIase, was discovered in Castellaniella defragrans, 
previously known as Alcaligenes defragrans.[71–73] This enzyme was shown to catalyse the 
reversible hydration of myrcene to geraniol via (S)-linalool (Figure 1.20).[74] As the 
equilibrium of this reaction lies towards myrcene the enzyme was named dehydratase rather 
than hydratase, and its ability to isomerise linalool to geraniol supplied the last part of its 
name. 
Figure 1.20 The reversible hydration and isomerisation reactions catalysed by the enzyme 
Linalool Dehydratase-Isomerase (LDIase) from C. defragrans. Dehydration from geraniol is 
favoured. 
This enzyme’s ability to enantioselectively hydrate the electron-rich carbon-carbon double 
bond of myrcene make it an attractive enzyme to study in an underpopulated class. Since 
myrcene is readily found in hops grown abundantly for the brewing industry, this enzyme 
could potentially produce a valuable fragrance from an inexpensive feedstock. 
Recent work in the Grogan group has solved the structure of this enzyme with geraniol 
(Figure 1.21), and suggests either a covalent or carbocation intermediate acid-base catalysed 
reaction for the dehydration of linalool to myrcene or its isomerisation to geraniol (Figure 
1.22).[75] However, the mechanism of its unique enantioselective hydration of myrcene to 
(S)-linalool and isomerisation of geraniol to the same requires further investigation, 
specifically how it is able to introduce chirality. 
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Figure 1.21 X-ray crystallographic structure of the LDIase pentamer, with molecules of the 
asymmetric unit labelled. 
Figure 1.22 Scheme of proposed covalent LDIase mechanism for the dehydration and 
isomerisation of linalool. Arrows in red indicate dehydration, and arrows in blue isomerisation. 
The mechanism of hydration can be deduced by following the reaction in reverse. 
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A full understanding of this reaction mechanism would allow for the rational design of this 
enzyme to improve its enantiomeric excess and, importantly, to increase substrate range. 
Patents have been filed which describe the random engineering of LDIase, allowing it to 
dehydrate crotyl alcohol to 1,3-butadiene and isoprenol to isoprene.[76–78] The polymers of 
these subunits are the main components of natural and synthetic rubber, providing a 
potentially petrochemical-free way of making incredibly valuable products.[79,80]
1.5.2. R. erythropolis Linalool Dehydratase-Isomerase (ReLDIase) 
Although LDIase has demonstrated the excellent ability to catalyse an important industrially 
useful reaction, it faces possible issues with oxygen-sensitivity.[71] R. erythropolis was found 
by Thompson et al. to catalyse the same reaction as LDIase, though before the publication of 
the latter.[59] The benefit of this is that R. erythropolis does not face these issues, and 
identification of a linalool dehydratase-isomerase homologue would provide a prospectively 
more industrially-applicable enzyme for biocatalysis. Heterologous expression, purification 
and crystallisation for structure solution would also confirm the enzymes’ similarities and 
any novel mechanistic features. 
1.6. Project aims 
The aims of this project are as follows: 
I. The expression, purification, and co-crystallisation of LDIase with linalool to 
structurally determine a Michaelis complex of the intermediate transition state. 
II. Mutagenesis studies of residues suspected to be essential in the catalytic mechanism, 
namely C171. Mutation of this residue to a serine could create a slow mutant, which 
can be structurally studied for a clearer understanding of the enzyme mechanism.[81]
III. The heterologous expression in E. coli using the pET-YSBLIC3C vector of the 
linalool dehydratase-isomerase homologue from R. erythropolis, putatively named 
ReLDIase, to determine an aerobic alternative to LDIase for industrial application. 
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Experimental Methods 
2.1. Materials 
2.1.1. Chemicals 
Chemicals were purchased from Fisher Scientific UK, Fluka Chemie GmbH, Formedium 
Ltd., Melford Biolaboratories Ltd., Merck KGaA, National Diagnostics, Sigma-Aldrich LLC, 
or VWR International bvba unless stated otherwise. 
Crystallisation screens were purchased from Hampton Research (Index HT) or Molecular 
Dimensions (PACT premier and CSS I & II). 
Restriction enzymes, agarose gel dyes, and agarose gel ladders were supplied by New 
England Biolabs (NEB). 
The majority of water used in this work is UPW, for type I ultrapure (> 18 MΩ·cm). 
2.1.2. Plasmids 
Gene for Rhodococcus erythropolis Linalool Dehydratase-Isomerase (ReLDIase) of 1698 bp 
was synthesised by Invitrogen (GeneArt) and hosted in the pMK-RQ (kanR) vector. 
The vector used for introduction of a cleavable N-terminal hexahistidine tag to genes of 
interest was pET-YSBLIC3C, a derivative of pET-28a, provided in-house. 
2.1.3. Primers 
Primers were synthesised by Eurofins Genomics, purified by HPSF (High Purity Salt Free) 
and provided in lyophilised format. 
Primers designed for LDIase mutagenesis are described in Table 2.1. 
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Table 2.1 Primers for C171S site-directed mutagenesis of LDIase by QuikChange. The positions 
of mutated nucleotides are highlighted in red. 
Primer name Tm / °C DNA sequence (5’ → 3’) 
LDI_C171S_FOR 75.1 CCGTTTGCCGGTATTGTTAGCGAACCGGATAACTATTTTG (40) 
LDI_C171S_REV 75.1 CAAAATAGTTATCCGGTTCGCTAACAATACCGGCAAACGG (40) 
LDI_t511a_FOR 79.45 GCAAATCCGTTTGCCGGTATTGTTAGTGAACCGGATAA (38) 
LDI_t511a_REV 79.45 TTATCCGGTTCACTAACAATACCGGCAAACGGATTTGC (38) 
Primers designed for ReLDIase LIC-based molecular cloning are described in Table 2.2. 
Table 2.2 Primers for LIC cloning of ReLDIase into pET-YSBLIC3C. The pET-YSBLIC3C 
complementary regions are highlighted in yellow, and the gene insert complementary regions in 
cyan. 
Primer name Tm / °C DNA sequence (5’ → 3’) 
ReLDI_F_LIC3C > 75 CCAGGGACCAGCAATGAGCAGCATTAGCCGTCGTAGCCTG (40) 
ReLDI_R_LIC3C > 75 GAGGAGAAGGCGCGTTAGGTCCATTTCAGGGTCACGGTGGTG (42) 
Primer designed for ReLDIase signal peptide cleavage is described in Table 2.3. 
Table 2.3 Primers for LIC cloning of ReLDIase into LIC3C, removing 81 N-terminal nucleotides (27 
amino acids) to create ReLDI-27ase. The pET-YSBLIC3C complementary regions are highlighted 
in yellow, and the gene insert complementary regions in cyan. 
Primer name Tm / °C DNA sequence (5’ → 3’) 
ReLDI-81_FOR > 75 CCAGGGACCAGCAATGAGCGCATGTAGCACCGCAACCACC (40) 
2.1.4. Growth media 
Growth media used for transformation include Super Optimal Broth (SOC) and NZY+, the 
former was supplied with chemically competent cells. Lysogeny Broth (LB) was used for 
both inoculation of starter cultures and in some expression experiments. Minimal Medium 
M9 was used for expression tests. Terrific Broth (TB) was used for the majority of large-
scale expression. 
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Water used in the preparation of all media is referred to as UPW, for type I ultrapure (> 18 
MΩ·cm). 
All autoclaving was carried out at 121 °C for 20 min. 
NZY+ Media 
NZ amine (casein hydrolysate)  2.0 g 
Yeast extract  1.0 g 
Sodium chloride (NaCl) 1.0 g 
UPW  200 mL 
→ autoclaved 
1 M MgCl2*  2.5 mL 
1 M MgSO4*  2.5 mL 
20 % w/v Glucose*  4 mL 
*addition after autoclaving step, carried out under aseptic conditions by filtration with a 
0.22 μm membrane. 
Adjustment of pH to 7.5 prior to autoclaving. Final composition divided into 1 mL aliquots 
for storage at -20 °C. 
Minimal Medium M9 
Sodium phosphate dibasic (Na2HPO4)  6.0 g 
Potassium phosphate monobasic (KH2PO4) 3.0 g 
Sodium chloride (NaCl) 0.5 g 
Ammonium chloride (NH4Cl)  1.0 g 
UPW  1000 mL 
→ autoclaved 
1 M Magnesium sulfate (MgSO4)*  1 mL 
0.1 M Calcium chloride (CaCl2)*  1 mL 
10 % w/v Glucose*  10 mL 
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*addition after autoclaving step, carried out under aseptic conditions by filtration with a 
0.22 μm membrane. 
Lysogeny Broth (LB) Media 
Sodium chloride (NaCl) 10.0 g 
Tryptone  10.0 g 
Yeast extract  5.0 g 
UPW  1000 mL 
→ autoclaved 
Terrific Broth (TB) Media 
Yeast Extract  24.0 g 
Tryptone  12.0 g 
Glycerol 4 mL 
UPW  900 mL 
→ autoclaved 
Phosphate Salts*  100 mL (10 % of total volume) 
*addition after autoclaving step, carried out under aseptic conditions using sterile 
equipment. 
Phosphate Salts 
Potassium phosphate dibasic (K2HPO4) 87.8 g  0.72 M 
Potassium phosphate monobasic (KH2PO4) 16.2 g  0.17 M 
UPW  700 mL 
→ autoclaved 
2.1.5. Buffers 
2.1.5.1. Protein purification buffers 
Three buffers were used for cell lysis and purification, and each has been assigned a signifier 
name to explain its purpose. Buffer A is the ‘Cell’ buffer, used for cell pellet resuspension and 
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to hold lysate. For these purposes it contains glycerol to maintain cell and protein stability, 
and imidazole to prevent non-specific protein binding during the nickel column loading 
step. Buffer B is the ‘Protein’ buffer, which contains no imidazole and is used as the major 
protein-holding liquid. Buffer C is the ‘Imidazole’ buffer, which contains a very high (500 
mM) concentration of imidazole to elute histidine-tagged, column-bound protein during 
IMAC purification by competing for the nickel immobilised to the resin. 
All three buffers were pH adjusted to 8.0, then vacuum filtered at 0.22 μm and degassed. 
Buffer A ‘Cell’ 
Sodium chloride (NaCl) 500 mM 14.6 g 
Tris  50 mM  3.0 g 
Imidazole (low-UV)  20 mM  0.7 g 
Glycerol 10 %  50 mL 
UPW  500 mL 
Buffer B ‘Protein’ 
Sodium chloride (NaCl) 500 mM 29.2 g 
Tris  50 mM  6.0 g 
UPW  1000 mL 
Buffer C ‘Imidazole’ 
Sodium chloride (NaCl) 500 mM 29.2 g 
Tris  50 mM  6.0 g 
Imidazole (low-UV)  500 mM 34.0 g 
UPW  1000 mL 
2.1.5.2. Electrophoresis buffers 
Tris-acetate-EDTA (TAE) Buffer (50x) 
Tris  242 g  10 mM 
Acetic acid glacial  57 mL  1 mM 
EDTA (0.5 M, pH 8.0)  100 mL 50 mM 
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UPW  to 1 L 
Adjustment of pH to 7.5 
SDS-PAGE Resolving Buffer 
Tris  1.5 M  pH 8.8 
SDS  10 % 
SDS-PAGE Stacking Buffer 
Tris  0.5 M  pH 6.8 
SDS  0.4 % 
SDS-PAGE Running Buffer Stock (4x) 
Glycine (electrophoresis grade) 115.2 g 
Tris  24.0 g 
UPW  2000 mL 
SDS-PAGE Running Buffer 
SDS-PAGE Running Buffer Stock (4x) 250 mL 
UPW  750 mL 
10 % (w/v) SDS 10 mL 
SDS-PAGE Sample Loading Buffer (2x) 
SDS-PAGE Stacking Buffer  1.2 mL 
50 % (w/v) Glycerol  2.0 mL 
10 % (w/v) SDS 2.0 mL 
1 % (w/v) Bromophenol blue  0.5 mL 
β-mercaptoethanol  0.5 mL 
UPW  3.8 mL 
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2.2. Mutagenesis 
2.2.1. Primer design 
Primers for mutagenesis were designed according to the requirements specified by the 
QuikChange Site-Directed Mutagenesis method. 
Primers LDI_C171S_FOR and LDI_C171S_REV were designed using the PrimerX primer 
design tool, selecting ‘QuikChange Site-Directed Mutagenesis Kit by Stratagene’ at step 4 
and ‘Escherichia coli’ at step 6 with default parameters. 
Primers LDI_t511a_FOR and LDI_t511a_REV were designed using the Agilent 
QuikChange Primer Design Program, selecting ‘QuikChange’ at step 2. 
2.2.2. PCR using PfuTurbo DNA polymerase 
PfuTurbo DNA polymerase (Agilent) was used for mutagenesis due to its high fidelity and 
ability to extend long DNA. A PCR reaction mixture of 50 μL was assembled as described in 
Table 2.4. Mg2+ was not added separately to the reaction mixture as it was present in the 
buffer. 
Table 2.4 PfuTurbo PCR reaction mixture. 
Component Stock Concentration Volume / μL 
Autoclaved UPW 36 
Cloned Pfu reaction buffer 10x 5 
dNTPs 2 mM each nucleotide 5 
DNA template (plasmid) ≥ 100 ng µL-1 1 
Forward primer 20 pmol µL-1 1 
Reverse primer 20 pmol µL-1 1 
PfuTurbo DNA polymerase 2.5 U µL-1 1 
Thermocycling parameters were set as described in Table 2.5 using a Bioer LifeECO thermal 
cycler. 
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Table 2.5 PfuTurbo PCR thermocycling parameters. 
Segment Cycles Temperature / °C Time / s 
Initialisation 1 95 300 
Denaturation 
18 
95 60 
Annealing 55 60 
Elongation 72 60 kb-1
Final elongation 1 72 300 
Cooling 1 4 120 
Hold 10 ∞ 
2.2.3. Touchdown PCR 
Touchdown PCR was used as a possible solution to the difficulties associated with high 
primer melting temperatures, such as poor template annealing and primer-dimer 
formation.[82] The PCR reaction mixture was assembled as described in Table 2.4 ut supra. 
Thermocycling parameters were set as described in Table 2.6. 
Table 2.6 Touchdown PCR thermocycling parameters. 
Segment Cycles Temperature / °C Time / s 
Initialisation 1 95 120 
Denaturation 
15 
95 30 
Annealing 72* 30 
Elongation 72 60 kb-1
Denaturation 
20 
95 30 s 
Annealing 64 30 s 
Elongation 72 60 kb-1
Final elongation 1 72 600 
Cooling 1 4 120 
Hold 10 ∞ 
*decreases by 0.5 °C each cycle 
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2.2.4. Digestion of parental plasmid DNA with DpnI 
To prevent the subsequent transformation of non-mutated parental plasmid DNA used as a 
template in the PCR reaction, DpnI was used to digest this E. coli-derived and thus 
methylated DNA. 
After thermocycling, 1.5 μL DpnI (2 units μL-1) was added to the PCR reaction mixture. The 
digest reaction was incubated at 37 °C for 4.5 hours. 
2.2.5. Transformation, DNA isolation and sequencing 
DpnI-digested DNA was transformed into E. coli XL10-Gold cells as in [2.4], but with 
addition of 5 μL DNA. 
Mutated plasmid DNA was isolated by miniprep as in [2.5].  DNA was sent to GATC Biotech 
AG for confirmation of the desired mutation by sequencing. 
2.3. Molecular cloning by LIC 
2.3.1. Primer design 
Primers for Ligation Independent Cloning (LIC) into pET-YSBLIC3C were designed using 
the HiTel Primer Design Service, University of York Bioscience Technology Facility. 
Primers were designed to have two parts; a pET-YSBLIC3C-complementary end and an 
insert-complementary end. The first 13 nucleotides from the 5’ end of the forward primer 
(5’-CCAGGGACCAGCA-3’), and the first 17 nucleotides from the 5’ end of the reverse primer 
(5’-GAGGAGAAGGCGCGTTA-3’) were LIC3C-complementary. The remainder of the 
primer was insert-complementary. The reverse primer also adds a stop codon (TAA) to the 
gene of interest. This method allows addition of LIC3C-specific overhangs to the insertion 
gene by amplification.[83]
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2.3.2. PCR using KOD Hot Start DNA polymerase 
KOD Hot Start DNA polymerase (Merck Millipore) was used for molecular cloning due to 
its fidelity, speed, and proofreading ability. A PCR reaction mixture of 50 μL was assembled 
as described in Table 2.7. 
Table 2.7 KOD Hot Start PCR reaction mixture. 
Component Stock Concentration Volume / μL 
Autoclaved UPW 33 
KOD Hot Start buffer 10x 5 
dNTPs 2 mM each nucleotide 5 
DNA template (plasmid) 1 
Forward primer 20 pmol µL-1 1 
Reverse primer 20 pmol µL-1 1 
KOD Hot Start DNA polymerase 1.0 U µL-1 1 
For standard PCR, thermocycling parameters were set as described in Table 2.8. 
Table 2.8 KOD Hot Start standard PCR thermocycling parameters. 
Segment Cycles Temperature / °C Time / s 
Initialisation 1 94 180 
Denaturation 
35 
94 30 
Annealing 55 30 
Elongation 72 60 kb-1
Final elongation 1 72 60 
Cooling 1 4 120 
Hold 10 ∞ 
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For touchdown PCR, thermocycling parameters were set as described in Table 2.9. 
Table 2.9 KOD Hot Start touchdown PCR thermocycling parameters. 
Segment Cycles Temperature / °C Time / s 
Initialisation 1 95 180 
Denaturation 
15 
95 60 
Annealing 70* 30 
Elongation 72 60 kb-1
Denaturation 
20 
95 60 
Annealing 55 30 
Elongation 72 60 kb-1
Final elongation 1 72 90 
Cooling 1 4 120 
Hold 10 ∞ 
*decreases by 1 °C each cycle 
2.3.3. Linearisation of pET-YSBLIC3C 
To allow insertion of a gene into the vector pET-YSBLIC3C, the circular DNA must be 
linearised. This was accomplished by digesting the vector using the BseRI restriction 
enzyme through the reaction described in Table 2.10. 
Table 2.10 pET-YSBLIC3C linearisation reaction mixture. 
Component Volume / μL 
Autoclaved UPW 700 
Circular pET-YSBLIC3C 180 
10x CutSmart buffer (NEB) 100 
BseRI 20 
Reaction was incubated at 37 °C for 110 min, then purified by agarose gel electrophoresis. 
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2.3.4. Agarose gel electrophoresis 
Separation of DNA for analysis or purification was performed by agarose gel electrophoresis 
using a Bio-Rad Mini-Sub Cell GT electrophoresis system. 
Agarose gel concentration was made to 1 % by dissolving 0.5 g agarose in 50 mL 1x TAE 
buffer by microwaving for 1 min, then addition of 1 μL SYBR Safe DNA gel stain before 
pouring. DNA was prepared by addition of 6x Purple Gel Loading Dye, and a 1 kb DNA 
ladder was loaded alongside samples. 
Electrophoresis was run in 1x TAE buffer at 100 V for 60 min, and visualised under UV 
light for analysis or using an Invitrogen Safe Imager for band excision. 
For DNA purification, the excised band of interest was purified using a GenElute Gel 
Extraction Kit (Sigma-Aldrich) according to the manufacturer’s instructions. DNA was 
incubated for 30 min in 65 °C water then eluted. 
2.3.5. T4 Polymerase treatment 
Following PCR amplification of insertion gene with LIC3C-complementary overhangs and 
subsequent gel purification, both insert and vector DNA was treated with LIC-qualified T4 
DNA polymerase (Novagen) to create sticky ends of the complementary regions. This was 
carried out as described in Table 2.11 and Table 2.12. 
Table 2.11 Gene insert T4 treatment reaction mixture. 
Component Volume 
10x T4 DNA polymerase buffer 2 μL 
dATP (25 mM) 2 μL 
DTT (100 mM) 2 μL 
LIC-qualified T4 DNA polymerase 0.4 μL 
Insertion gene w/ overhangs to final concentration of 0.2 pmol 
Autoclaved UPW to 20 μL 
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Table 2.12 Linear pET-YSBLIC3C T4 treatment reaction mixture. 
Component Volume 
10x T4 DNA polymerase buffer 6 μL 
dTTP (25 mM) 6 μL 
DTT (100 mM) 3 μL 
LIC-qualified T4 DNA polymerase 1.2 μL 
Linear pET-YSBLIC3C to final concentration of 0.6 pmol 
Autoclaved UPW to 60 μL 
Each reaction was incubated at 22 °C for 30 min, then 75 °C for 20 min. LIC3C reaction was 
purified by agarose gel electrophoresis. 
2.3.6. Annealing 
To anneal the insertion gene to pET-YSBLIC3C, both were incubated with each other at 
ratios of 1:1, 5:1, and 1:5 for 10 min at room temperature. This was followed by addition of 
1 μL EDTA (25 mM) and incubation for a further 10 min at room temperature. Each 
reaction mixture was transformed into chemically competent E. coli as in [2.4]. 
2.3.7. Colony PCR 
A master mix was assembled by multiplying Table 2.13 by the total number of colonies 
required for testing, then dividing appropriately into 25 μL reactions. 
Table 2.13 Taq colony PCR reaction mixture master mix (1×). 
Component Volume / μL 
Autoclaved UPW 18.6 
10x standard Taq reaction buffer 2.50 
dNTPs (2 mM each nucleotide) 2.50 
MgSO4 (50 mM) 0.75 
Forward primer 0.25 
Reverse primer 0.25 
Taq DNA polymerase 0.10 
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2 colonies were picked per plate, and each was touched to a division on an antibiotic agar 
plate (incubated at 37 °C), then rinsed in a 25 μL PCR reaction tube. Thermocycling 
parameters were as follows in . 
Table 2.14. 
Table 2.14 Taq colony PCR thermocycling parameters. 
Segment Cycles Temperature / °C Time / s 
Initialisation 1 95 30 
Denaturation 
30 
95 30 
Annealing 55 60 
Elongation 68 60 kb-1
Final elongation 1 68 300 
Cooling 1 4 120 
Hold 10 ∞ 
PCR was analysed by agarose gel electrophoresis, and successful colonies were picked from 
the division plate to inoculate starter cultures for miniprep to carry out a restriction digest. 
2.3.8. Double restriction digest 
Plasmids were analysed for successful cloning based on known patterns of fragmentation 
from digestion with restriction enzymes, using the following reaction as in Table 2.15. 
Table 2.15 Double restriction digest reaction mixture. 
Component Volume / μL 
Plasmid DNA 7 
10x CutSmart buffer (NEB) 1 
NcoI 1 
NdeI 1 
Reaction was incubated at 37 °C for 180 min in a thermocycler. This was subsequently 
analysed by agarose gel electrophoresis. 
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2.4. Transformation into E. coli XL10-Gold for plasmid yield 
Chemically competent E. coli XL10-Gold supplied by Agilent. Chemical competence by 
calcium chloride treatment increases membrane-DNA interactions.[84] A rapid change in 
temperature (heat shock) causes membrane pore formation allowing entry of proximal 
plasmid DNA.[85]
Transformation protocol followed manufacturer’s instructions: 
1) E. coli XL10-Gold competent cells thawed on ice and 50 μL mixed with 2 μL β-
mercaptoethanol by gentle pipetting 
2) Incubation on ice for 10 min with swirling 
3) Addition of 1 μL plasmid DNA, gentle pipetting to mix 
4) Incubation on ice for 30 min with swirling 
5) Heat shock at 42 °C for 30 s in heat block 
6) Incubation on ice for 2 min 
7) Addition of 450 μL NZY+ media warmed to 42 °C, gentle pipetting to mix 
8) Incubation at 37 °C for 1 h while shaking at 200 RPM 
9) 100 μL spread onto warm antibiotic agar plate (LB-kan); incubation at 37 °C 
overnight 
2.5. Plasmid isolation by minipreparation 
Plasmid DNA was isolated by miniprep, based on the alkaline lysis of cells and selective 
adsorption of plasmid DNA to a silica membrane. To prepare a starter culture, a 50 mL 
Falcon tube containing 5 mL autoclaved LB media with antibiotic (kanamycin at 50 μg mL-
1) was inoculated with a single colony of E. coli containing the plasmid of interest using a 
pipette tip. This was then placed in a shaker-incubator at 37 °C and 200 RPM overnight. 
Cultures were harvested by centrifugation using a Sigma 3-16KL with rotor 1180 & 13190 
at 3894 RCF. Plasmid isolation was carried out with a QIAprep Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions, eluting in 65 °C water. Centrifugation steps 
were carried out at 16,300 RCF using a Progen GenFuge 24D. 
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The DNA concentration was measured using the dsDNA function of an Eppendorf 
BioPhotometer plus. 
2.6. Transformation into E. coli BL21(DE3) for expression 
Chemically competent E. coli BL21(DE3) supplied by New England Biolabs (catalog number 
C2527H) were used as the heterologous expression host. 
Transformation protocol followed manufacturer’s instructions: 
1) 50 μL tube of E. coli BL21(DE3) competent cells thawed on ice for 10 min 
2) Addition of 1 μL plasmid DNA, gentle pipetting to mix 
3) Incubation on ice for 30 min 
4) Heat shock at 42 °C for 10 s in heat block 
5) Incubation on ice for 5 min 
6) Addition of 950 μL SOC media, gentle pipetting to mix 
7) Incubation at 37 °C for 1 h while shaking at 200 RPM 
8) 100 μL spread onto warm antibiotic agar plate (LB-kan); incubation at 37 °C 
overnight 
2.7. Expression tests 
Many factors affect the expression levels of recombinant genes, and thus the concentration 
and solubility of produced protein. These can include expression host, growth media, and 
induction temperature. An expression test allows analysis of gene expression while varying 
each of these factors, thus determining the ideal expression conditions. 
A 5 mL starter culture of each transformant containing the enzyme plasmid in either E. coli
BL21(DE3) or Rosetta(DE3) (Novagen) was made [2.6]. A 50 mL Falcon tube containing 10 
mL of the test media with appropriate antibiotic(s) was prepared for each temperature and 
inoculated with 50 μL starter culture. For each tube, an identical control was prepared which 
would not be induced with IPTG. 
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All tubes were placed in a shaker-incubator at 37 °C and 200 RPM until an OD600 of 1.7-2.0 
(TB media) or 0.6-0.8 (M9 and LB media) was reached. Tubes other than the controls were 
induced with 1 mM IPTG (1M stock) and placed in a shaker-incubator set to the appropriate 
temperature and 180 RPM overnight. 
Cultures were harvested by centrifugation using a Sigma 3-16KL with rotor 1180 & 13190 
at 3894 RCF. Cell pellets were resuspended in 1 mL Buffer A and transferred to a 96-well 
block for sonication using a 24-tip multisample sonicator by repeating 90 cycles of 1 s 
sonication then 1 s cooling. 
Soluble and insoluble fractions were separated by centrifugation using a Sigma 2K15 with 
rotor Nr.12148 at 15,000 RCF for 60 min at 4 °C. Each fraction was analysed by SDS-PAGE. 
2.8. Gene expression 
E. coli BL21(DE3) encodes an IPTG-inducible T7 RNA polymerase gene, which transcribes 
the gene of interest by binding to a T7 promoter site preceding the hexahistidine tag of pET-
YSBLIC3C. IPTG is a lactose mimic which inactivates T7 repression at the lac operon, 
maintaining continuous T7 transcription as it is not metabolised. This allows 
overexpression of the gene of interest to produce protein at levels substantially higher than 
would normally be possible. 
To uniformly inoculate multiple media, a starter culture of transformant E. coli BL21(DE3) 
containing the enzyme plasmid was made. Two 50 mL Falcon tubes containing 10 mL 
autoclaved LB media with antibiotic (kanamycin at 50 μg mL-1) was inoculated with a single 
colony from [2.6], then placed in a shaker-incubator at 37 °C and 200 RPM overnight. 
Ultra-Yield flasks (2.5 L) were prepared with 1 L TB media each and autoclaved [2.1.4]. 
Under sterile conditions, 100 mL Phosphate Salts, 1 mL kanamycin (1:1000, 50 mg mL-1
stock) and 2 mL prepared starter culture from a single tube was added to each flask, then 
placed in a shaker-incubator at 37 °C and 300 RPM. 
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Upon reaching an OD600 of 1.7-2.0 (TB media) or 0.6-0.8 (M9 and LB media), 1 mM IPTG 
(1M stock) was added for induction and flasks placed in a shaker-incubator at 16 °C and 250 
RPM overnight. 
2.9. Cell lysis 
Flasks retrieved from shaker-incubator and contents centrifuged using a Beckman Coulter 
Avanti J-HC with a JLA-8.1000 rotor at 5000 RCF for 25 min at 4 °C. 
Cell pellets may be transferred to 50 mL Falcon tubes and frozen in liquid nitrogen. For 
continuation, cell pellets were resuspended in 2 mL g-1 Buffer A, then stirred at 4 °C to 
ensure homogeneity. 
Cell lysis was performed by physical disruption, either through sonication or pressure. In 
the case of the former, the cell suspension was sonicated on ice using a MSE Soniprep 150 
Plus by repeating 15 cycles of 30 s sonication then 45 s cooling with frequent swirling. 
For the latter, a Constant Systems Ltd. Cell Disruptor was rinsed with water at 5 kpsi before 
loading cell suspension for lysis at 25 kpsi. This was followed by a rinse with Buffer A and 
lysate collection. System was cleaned at 5 kpsi with water then Triton detergent, and left in 
20 % ethanol. 
Lysate clarified by centrifugation using a Sorvall Evolution RC with a SS34 rotor at 50,000 
RCF for 60 min at 4 °C. Supernatant filtered and loaded at 40 mL h-1 onto a HisTrap FF 
Crude (5 mL) column (GE Healthcare) equilibrated with Buffer A, using a Peristaltic Pump 
P-1 (GE Healthcare). 
2.10. Protein purification 
2.10.1. Immobilized metal affinity chromatography (IMAC) 
The six histidine residues incorporated onto the enzyme N-terminus by pET-YSBLIC3C 
form coordination bonds with nickel (Ni2+) immobilised to the agarose-derived sepharose 
in the column. This retains the protein of interest in the column, allowing other undesired 
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proteins and soluble cellular substances to pass through. At this stage, an imidazole gradient 
is applied with a chromatography system and fractions are collected. Imidazole has 
competitive affinity for nickel, displacing histidine and freeing the protein into the buffer 
solution. Hexahistidine-tagged proteins will elute at a specific concentration of imidazole in 
the gradient, which is measured by UV as a chromatogram. 
An ÄKTA chromatography system (GE Healthcare) was pump washed through lines B 
(Buffer C) then A (Buffer B). The protein-loaded HisTrap FF Crude column was connected 
and an affinity chromatography programme run. The programme consisted of the steps 
summarised in Table 2.16. 
Table 2.16 IMAC purification programme for HisTrap FF Crude columns using ÄKTA systems. 
Step Liquid composition as % of Line B Volume passed / mL 
Wash 0 25 
Low Imidazole Wash 4 25 
Gradient Elution 4 - 100 100 
Final Elution 100 25 
The flow rate was set to 2.5 mL min-1, and elute was collected as 1.8 mL fractions. These 
were subsequently analysed by SDS-PAGE. 
2.10.2. Size exclusion chromatography (SEC) 
Size exclusion chromatography relies on the separation of proteins based on their size, 
accomplished through the use of beads with a range of pore sizes. Small proteins can pass 
through more of these sizes than large proteins; thus the smaller the protein the more slowly 
it traverses the column, and the later it is eluted. For crystallography, this technique is used 
as a ‘polishing’ step and is particularly suitable for separating protein oligomers. 
An ÄKTA chromatography system (GE Healthcare) was pump washed through lines B 
(Buffer B) then A (UPW, filtered and degassed). A HiLoad 16/600 Superdex 75 pg or 200 pg 
column (Ge Healthcare) was connected and an equilibration programme run as summarised 
in Table 2.17. The flow rate was set to 1.0 mL min-1. 
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Table 2.17 Equilibration programme for HiLoad 16/600 Superdex columns using ÄKTA systems. 
Step Liquid composition as % of Line B Volume passed / mL 
Wash 0 120 (1.0 CV) 
Equilibration 100 132 (1.1 CV) 
Selected fractions collected from IMAC and analysed by SDS-PAGE were pooled and 
concentrated to < 2 mL in a Vivaspin 20 30k MWCO (Sartorius), using a Sigma 3-16KL 
centrifuge with a 1180 & 13190 rotor at 3894 RCF and 4 °C. 
Concentrated protein was injected onto the ÄKTA system with a 2 mL loop and a SEC 
programme run. The programme consisted of the steps summarised in Table 2.18. 
Table 2.18 SEC purification programme for HiLoad 16/600 Superdex columns using ÄKTA 
systems. 
Step Liquid composition as % of Line B Volume passed / mL 
Wash 100 20 
Elution 100 100 
The flow rate was set to 1.0 mL min-1, and elute was collected as 1.8 mL fractions. These 
were subsequently analysed by SDS-PAGE. 
Selected fractions were pooled and concentrated to 4 mg mL-1 for flash-freezing and storage 
at -80 °C, or the appropriate concentration for crystallisation trials. 
2.11. SDS-PAGE 
Sodium dodecyl sulfate denatures proteins, allowing them to be analysed by secondary 
structure against molecular markers. The polyacrylamide gel restricts electric field-induced 
migration based on molecular mass (kDa). 
SDS-PAGE gels were prepared at an acrylamide concentration of 12 %, as described in Table 
2.19 and Table 2.20. Butan-1-ol was used to maintain a level surface during resolving gel 
polymerisation, before layering with the stacking gel and comb. 
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Table 2.19 SDS-PAGE resolving gel (2×). 
Component Volume 
Autoclaved UPW 3.2 mL 
SDS-PAGE Resolving Buffer 2.5 mL 
Acrylamide 4.2 mL 
10 % APS 50 μL 
TEMED 8 μL 
Table 2.20 SDS-PAGE stacking gel (2×). 
Component Volume 
Autoclaved UPW 3.2 mL 
SDS-PAGE Stacking Buffer 1.3 mL 
Acrylamide 0.5 mL 
0.1 % bromophenol blue 10 μL 
10 % APS 25 μL 
TEMED 8 μL 
Protein samples were prepared by addition of 2x SDS-PAGE Sample Loading Buffer, then 
heated at 95 °C for 5 min. A low Mw ladder was loaded alongside samples. 
SDS-PAGE was run in SDS-PAGE Running Buffer at 200 V for 50 min, and stained with 
Coomassie. 
2.12. Protein crystallisation 
The vapour diffusion crystallisation method utilised in this work relies on the formation of 
vapour equilibration between the crystallisation condition reservoir and a drop of protein 
mixed with crystallisation condition. Vapour diffuses from the drop to the reservoir in a 
closed system, increasing the protein concentration to supersaturation for arrangement into 
crystals. This can either be performed by sitting drop or hanging drop method. 
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2.12.1. Sitting drop vapour diffusion 
Sitting drop vapour diffusion crystallisation was carried out in 96-well format for condition 
screening. 
A Hydra 96 (Robbins Scientific) was used to dispense 54 μL of each crystallisation condition 
into a 96-well MRC Wilden plate. A Mosquito LCP (TTP Labtech) mixed 150 nL SEC-
purified protein with 150 nL crystallisation condition from the reservoir. 
2.12.2. Hanging drop vapour diffusion 
Wells of a 24-well cell culture plate (Cellstar) were filled with the constituent reagents of 
individual crystallisation conditions as defined by the manufacturer, with appropriate 
adjustment for optimisation. SEC-purified concentrated protein was mixed with well 
crystallisation condition on a siliconized glass coverslip, which was subsequently inverted 
and secured over the well with high vacuum grease (Dow Corning). 
2.13. X-ray crystallography 
The ordered arrangement of crystals can uniformly diffract an incidence beam of X-ray 
radiation, providing a diffraction pattern. This is subjected to Fourier transformation for 
conversion into a map of the protein’s electron density, which is used as an ‘outline’ for 
secondary sequence orientation into a three-dimensional structure. Synchrotron light 
provides high-intensity radiation for collection of high-resolution electron density. Phases 
are refined using homologous proteins as molecular models. 
Crystals were transferred into a cryoprotectant solution of the mother liquor containing 
15% ethylene glycol and 5 mM linalool before flash-cooling with liquid nitrogen. A full 
dataset for LDIase C171S mutant was collected on beamline I02 at the Diamond Light 
Source, Didcot, Oxfordshire, U.K.  Data were processed and integrated using XDS[86] and 
scaled using SCALA[87] within the Xia2[88] processing system. Data collection statistics can 
be found in Table 4.2 (in [Chapter 4]). The structures were solved with MOLREP[89] using 
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one subunit of the structure of native LDIase (determined in the Grogan group) as the 
molecular replacement model. The structure was refined using iterative cycles of the 
programmes COOT[90] and REFMAC.[91]
2.14. LC-MS/MS 
LC-MS/MS was performed by Dr Adam Dowle at the University of York Biosciences 
Technology Facility. 
Samples separated by SDS-PAGE were excised, then destained and digested with Asp-N. 
LC-MS/MS analysis was performed over a 20 min gradient of elution. 
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C. defragrans Linalool Dehydratase-Isomerase (LDIase) 
3.1. Expression and purification 
A geraniol-bound complex of LDIase has previously been solved in the Grogan group 
through the use of a selenomethionine-substituted protein to overcome the phase problem. 
To develop a deeper understanding of the active site ligand-binding residues and possibly 
demonstrate a covalent intermediate, this project’s initial objective was to use co-
crystallisation methods to solve a linalool-bound complex. 
The gene for the native enzyme Linalool Dehydratase-Isomerase from Castellaniella 
defragrans was cloned earlier into the pET-YSBLIC3C plasmid by S. Chambers. For the 
present work, a glycerol stock of bacteria containing this plasmid was used to isolate the 
DNA by miniprep with a yield of 130 ng μL-1 [2.5]. 
Isolated plasmid was transformed into E. coli BL21(DE3) [2.6] and expressed in 3 L TB media 
[2.8]. Following a former successful method, cells were lysed by pressure homogenisation 
before nickel-based immobilised metal ion affinity chromatography (IMAC) (Figure 3.1 and 
Figure 3.2). Although the UV absorbance indicated a high volume of eluted protein during 
IMAC purification on an ÄKTA start [2.10.1], the protein experienced high levels of 
precipitation upon concentration which made it unsuitable for size exclusion 
chromatography (SEC). 
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Figure 3.1 Chromatogram of IMAC-purified native LDIase using an ÄKTA start, expressed in 3 L 
TB media and lysed by pressure homogenisation. The UV absorbance is shown in blue, with the 
imidazole gradient in green. 
Figure 3.2 SDS-PAGE of selected LDIase fractions from IMAC purification. Lane (1): low 
molecular weight marker; lanes (2-12): 5 mL fractions eluted by increasing imidazole 
concentration. 
To prevent this precipitation, the purification procedure was repeated using sonicated 
rather than pressure homogenised cells, from 1 L TB expression rather than 3 L. 
Unfortunately, this provided a substantially reduced protein yield by IMAC (Figure 3.3 and 
Figure 3.4). 
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Figure 3.3 Chromatogram of IMAC-purified LDIase using an ÄKTA start, expressed in 1 L TB 
media and lysed by sonication. The UV absorbance is shown in blue, with the imidazole gradient 
in green. 
Figure 3.4 SDS-PAGE of selected LDIase fractions from IMAC purification. Lane (1): low 
molecular weight marker; lanes (2-10): 5 mL fractions eluted by increasing imidazole 
concentration. 
Nonetheless, fractions eluted between 85-105 mL were pooled and concentrated for SEC on 
an ÄKTA start the same day to prevent possible protein degradation [2.10.2] (Figure 3.5 and 
Figure 3.6). 
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Figure 3.5 Chromatogram of SEC-purified LDIase using a HiLoad 16/600 Superdex 75 pg column 
attached to an ÄKTA start. 
Figure 3.6 SDS-PAGE of selected LDIase fractions from SEC purification. Lane (1): low molecular 
weight marker; lane (2): filtered clarified cell lysate; lane (3): pooled IMAC-purified protein; lanes 
(4-12): 5 mL fractions eluted by increasing imidazole concentration. 
Although SEC fractions eluted between 40-45 mL were pooled, concentrated to 10 mg mL-
1 and flash frozen in liquid nitrogen for storage at -80 °C, the yield was too low for 
crystallisation trials. As such, protein previously purified by A. Hau & H. Man was used for 
co-crystallisation experiments with linalool. 
3.2. Sitting drop crystallisation trials 
Native LDIase purified by A. Hau & H. Man was concentrated to 10 mg mL-1 and used to set 
up 96-well MRC Wilden plates for PACT, Index, and CSS I & II (with MES pH 6.0 and Tris 
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pH 8.0) [2.12.1]. For co-crystallisation with linalool, a 250 mM linalool stock in ethanol was 
used to give each mother liquor a linalool concentration of 0.5 mM. 
After three days’ incubation, crystal hits were observed across all three screens as noted in 
Table 3.1 and Figure 3.7. 
Table 3.1 Sitting drop crystallisation screens showing successful hit conditions. 
Crystallisation screen Hit conditions Chemical composition 
CSS 
(+ 0.1 M MES pH 6.0) 
D1 (CSS I) 0.3 M Sodium acetate; 8 % PEG 20,000; 8 % PEG 
550 MME 
F6 (CSS II) 0.2 M Calcium acetate; 8 % PEG 20,000; 8 % PEG 
550 MME 
Index B6 1.4 M (4.0 M NaH2PO4 + 4.0 M K2HPO4); pH 6.9 
E11 0.02 M Magnesium chloride; 0.1 M HEPES; 22 % 
w/v Poly(sodium acrylate) 5100; pH 7.5 
PACT F10 0.02 M (4.0 M Na2HPO4 + 4.0 M KH2PO4); 0.1 M Bis-
Tris propane; 20 % w/v PEG 3350; pH 6.5 
H12 0.2 M Sodium malonate dibasic monohydrate; 0.1 
M Bis-Tris propane; 20 % w/v PEG 3350; pH 8.5 
Figure 3.7 Crystals from sitting drop screens of C. defragrans LDIase. (A): CSS D1; (B): CSS F6; 
(C): Index B6; (D): Index E11; (E): PACT F10; (F): PACT H12. 
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3.3. Optimisation trials for native LDIase purification 
To produce LDIase for hanging drop vapour diffusion crystallisation scale-up trials, further 
attempts were made at purification for high yield and sufficient purity for crystal formation. 
Cell pellets from 2 L TB expression that had been flash frozen were lysed by pressure 
homogenisation and purified by IMAC on an ÄKTA explorer (Figure 3.8). 
Figure 3.8 Chromatogram of IMAC-purified LDIase using an ÄKTA explorer, expressed in 2 L TB 
media and lysed by pressure homogenisation. The UV280nm absorbance is shown in blue, UV254nm
in red, and the imidazole gradient in green. 
Fractions eluted between 295-323 mL were pooled and concentrated for SEC on the same 
system (Figure 3.9). 
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Figure 3.9 Chromatogram of SEC-purified LDIase using a HiLoad 16/600 Superdex 75 pg column 
attached to an ÄKTA explorer. The UV280nm absorbance is shown in blue, and the UV260nm
absorbance in red. 
Figure 3.10 SDS-PAGE of selected LDIase fractions from SEC purification. Lane (1): low molecular 
weight marker; lane (2): HisTrap FF Crude column loading flow-through; lane (3): IMAC-
purification wash; lane (4): pooled IMAC-purified protein; lanes (5-15): 1.8 mL buffer-eluted 
fractions. 
Although the chromatogram and SDS-PAGE gel (Figure 3.10) indicated pure protein, 
crystallisation did not occur with most of the protein precipitating in droplets. Further 
experiments in native LDIase purification failed to achieve crystallisable protein. 
3.4. Linalool hanging drop crystallisation 
24-well hanging drop vapour diffusion crystallisation trays were made for the successful 
sitting drop trial conditions Index B6, PACT F10, PACT H12, CSS D1 and CSS F6. Index 
E11 could not be made as polyacrylic acid 5100 was not available. Protein was used at a 
concentration of 10 mg mL-1 and 10 μL of a 50 mM stock of linalool solution in ethanol was 
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added to make a final linalool concentration of 0.5 mM in each well. Of these conditions, 
only PACT F10 yielded good quality crystals. 
To test whether the ethanol present in the linalool stock affected crystal growth, the PACT 
F10 condition was repeated, however rather than adding the 50 mM linalool stock, 1.1 μL 
of source linalool was added to each well of the lower two rows. This appeared to show little 
difference in the resulting crystals. 
An additive screen for the purpose of optimisation to develop larger crystals by slower 
growth was made. Ethylene glycol and glycerol were varied by 1-5 %, and ratios of 2:1 and 
1:1 of protein to condition were trialled. Conditions with ethylene glycol and drops in a ratio 
of 2:1 grew the best crystals. This was carried out over all the original conditions used for 
hanging drop, however PACT F10 remained the most successful. 
Additional optimisation adjusted PEG 3350 from 14-24 %; ethylene glycol from 2-6 %; and 
sodium/potassium phosphate from 14-24 mM. Protein to condition ratios were varied as 
above, using 2:1 and 1:1. Many large crystals resulted from these, specifically the 2:1 drops, 
however 14 % PEG 3350 and 24 mM sodium/potassium phosphate with 2% ethylene glycol 
yielded the best. 
To test other protein to condition ratios, another optimisation in PACT F10 was set up 
using ratios of 1:1, 2:1, 1:2, and 3:1 respectively. However, this gave inconsistent results with 
sporadic differences in crystal quality. 
Although some of the best crystals amongst the hanging drop optimisations generated good 
diffraction patterns and data was collected, a brief examination of the datasets did not show 
ligand density. Therefore, further PACT F10 24-well trays were made with the linalool 
concentration increased from 0.5 mM in each well to 5 mM, with variations in ethylene 
glycol of 4-6 % and PEG 3350 of 12-14 % (Figure 3.11). Even with this increase the substrate-
complexed structure continued to remain elusive. Crystal soaking over a period of 
approximately four hours also did not yield such ligand density from collected datasets. 
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Figure 3.11 Hanging drop crystals of LDIase in 5 mM linalool. (A): 14 % PEG & 4 % ethylene glycol; 
(B): 24 mM sodium/potassium phosphate & 2 % ethylene glycol. 
3.5. Geraniol hanging drop crystallisation 
It is reported by the literature that the equilibrium of the LDIase enzyme lies towards 
myrcene.[71] Therefore, a possible method for forming a linalool complex may be to co-
crystallise the enzyme with geraniol rather than linalool to ‘trap’ it in a complex after 
substrate conversion. 
Hanging drop trays were set up as for linalool, however using 5 mM geraniol in each well. 
PACT F10 was used, varying PEG 3350 from 12-14 % across one axis, and ethylene glycol 
from 4-6 % across the other. Crystal yield was high, with the best found in 14 % PEG 3350 
with 6 % ethylene glycol. Soaking of these crystals with geraniol as above was also attempted. 
These crystals diffracted well and supplied datasets, however without ligand density. 
3.6. LC-MS/MS 
To supply further evidence of a covalent LDIase-linalool intermediate complex, LC-MS/MS 
analysis of SDS-PAGE separated samples was performed by Adam Dowle of the Bioscience 
Technology Facility [2.14] (Figure 3.12). If the suspected residues involved in intermediate 
formation Cys 171 or Cys 180 were covalently bound to linalool, a mass addition of 122.1 
Da to one of these peptide residues should be observed over the untreated control. 
Unfortunately, no such mass addition was identified. Repeating this experiment with C171S 
or C171A ‘slow’ mutants may encourage retention of the prospective intermediate. 
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Figure 3.12 SDS-PAGE of LDIase incubated in linalool for LC-MS/MS analysis. 
3.7. Conclusions 
Repeated attempts at co-crystallisation of native LDIase did not yield any ligand-bound 
complexes or any indication of such. As the protein used had previously produced a ligand-
bound complex, this was unlikely to be the source of the issue. It is possible that the ethanol 
used to solubilise linalool for accurate concentration control during addition inactivated the 
enzyme. However, trays set up without ethanol by direct addition of linalool also failed to 
present a ligand-bound complex. This could indicate a problem with the compatibility with 
LDIase of the co-crystallisation method used, or could encourage optimisation of soaking 
length. 
As an alternative method for determining the existence of a covalent intermediate and 
ligand-binding determinants, the investigation of the cysteine believed to form the covalent 
bond to the intermediate could be performed. Two mutants can be used for this; serine 
(C171S) and alanine (C171A) would both have steric similarities to C171 and allow for the 
creation of a ‘slow’ mutant to hold the predicted intermediate during X-ray diffraction.[81]
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4.1. Mutagenesis 
Mutagenesis was carried out as a variation of the QuickChange method described in section 
[2.2] using touchdown PCR and SOC media without β-mercaptoethanol for transformation, 
however no colonies grew. The competency of XL-10 Gold cells was verified by a control 
transformation, which was successful. This indicated a problem with the PCR step. A series 
of optimisations were attempted in order to determine and overcome this limiting step, as 
summarised in Table 4.1. 
Table 4.1 Rounds of LDIase C171S mutagenesis attempts using LDI_C171S_FOR and 
LDI_C171S_REV primers. Each attempt was followed the same protocol, but with the exceptions 
described. 
Attempt Condition changed Details 
1 Initial mutagenesis 
2 
Larger graduations for PCR temperature 
stepdown of touchdown cycle 
1 °C annealing temperature decrease  
for each cycle changed to 0.5 °C 
3 
Use of standard thermocycling 
conditions to replace touchdown 
Annealing temperature for each  
cycle changed to 55 °C, for 30 cycles 
4 Dilution of template DNA 
1 μL of 10 ng μL-1 DNA added  
instead of 130 ng μL-1
5 Change in DNA polymerase 
Pfu Turbo replaced with KOD Hot Start 
(replacing 1 μL H2O with 25 mM 
MgSO4) 
6 Addition of DMSO 
1 μL DMSO added to reaction  
for 2 % total concentration 
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None of these changes yielded colonies after the transformation step. The issue was 
suspected to lie with the mutagenesis primers, and thus new primers were designed with a 
single base change and higher melting temperature. 
Newly designed primers were used for mutagenesis [2.2]. Colonies successfully grew and 
DNA was isolated by miniprep [2.5]. 
4.2. Expression and purification 
Isolated LDIase C171S mutant plasmid DNA was transformed into E. coli BL21(DE3) [2.6] 
and expressed in 2 L TB media [2.8]. Cells were lysed by sonication [2.9] and purified initially 
by IMAC [2.10.1] on an ÄKTA pure (Figure 4.1). SDS-PAGE analysis provided further 
information on the fractionation contents [2.11] (Figure 4.2). 
Figure 4.1 Chromatogram of IMAC-purified LDIase mutant C171S using an ÄKTA pure, expressed 
in 2 L TB media and lysed by sonication. The UV absorbance is shown in blue, with the imidazole 
gradient in green. 
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Figure 4.2 SDS-PAGE of selected LDIase mutant C171S fractions from IMAC purification. Lanes 
(1 & 30): low molecular weight marker; lane (2): 1:10 dilution of the insoluble fraction; lane (3): 1:5 
dilution of the unfiltered clarified cell lysate; lane (4): 1:5 dilution of the filtered clarified cell lysate; 
lane (5): HisTrap FF Crude column loading flow-through; lane (6): IMAC-purification wash; lanes 
(7-29): 1.8 mL fractions eluted by increasing imidazole concentration. 
Interestingly, the IMAC chromatogram showed a visibly different peak to native LDIase 
chromatograms. Rather than a single peak or a doublet peak, a triplet peak is observed. This 
could be due to better purification, or a chromatographic difference from the mutation. 
SDS-PAGE analysis indicated the first peak of the triplet was not pure and contained many 
proteins of the incorrect size. The second peak was shown to contain the protein of interest 
with a smaller-sized impurity. The third and final sloped peak contained the pure protein of 
interest (fractions 2B9-2C12), which was pooled and concentrated for SEC using an S200 
16/600 pg column on an ÄKTA pure [2.10.2] (Figure 4.3). 
Figure 4.3 Chromatogram of SEC-purified LDIase mutant C171S using a HiLoad 16/600 Superdex 
200 pg column attached to an ÄKTA pure. 
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Figure 4.4 SDS-PAGE of selected LDIase mutant C171S fractions from SEC purification. Lane (1): 
low molecular weight marker; lane (2): pooled IMAC-purified protein; lane (3): SEC-purification 
waste; lanes (4-15): 1.8 mL buffer-eluted fractions. 
The SEC chromatogram also showed three peaks, compared to the two given by the native 
enzyme. SDS-PAGE analysis (Figure 4.4) showed that the second, tallest peak had the 
cleanest protein. This was also suspected to be the correct oligomeric conformation for 
crystallisation, however details of the oligomer could not be determined without running 
an Analytical SEC experiment. Fractions from this peak (2C1-2C4) were pooled and used 
for crystallisation trials. 
4.3. Crystallisation 
LDIase C171S protein was concentrated and used to set up 96-well MRC Wilden plates for 
PACT, Index, and CSS I & II (with MES pH 6.0 and Tris pH 8.0) [2.12.1]. The top well used 
a protein concentration of 12 mg mL-1 and the bottom well 6 mg mL-1. 
Crystals were found in PACT F10, Index E11 and CSS D4 (MES pH 6.0), all at 12 mg mL-1
(Figure 4.5). 
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Figure 4.5 Crystals from sitting drop screens of LDIase mutant C171S added at a concentration 
of 12 mg mL-1. (A): PACT F10; (B): Index E11; (C): CSS D4 (+ MES pH 6.0). 
PACT F10 and Index E11 provided the best crystals, and so were selected for expansion to 
24-well hanging drop crystallisation. In hanging drop optimisation of both screens, all three 
condition components were adjusted. For PACT F10, PEG 3350 ranged from 16-22 %; bis-
tris propane from 80-120 mM; and sodium/potassium phosphate from 10-30 mM. For 
Index E11, poly(acrylic acid sodium salt) 5,100 ranged from 18-24 %; HEPES 0.1 M from pH 
7.0-8.0; and magnesium chloride hexahydrate from 10-30 mM. 
To attempt to gain a substrate-bound complex of the mutant, the conditions above were 
repeated with co-crystallisation using a method different than that which had unsuccessfully 
been attempted for the native protein. For a linalool concentration of 10 mM, 0.13 μL 
linalool was added to 100 μL LDIase C171 protein at 8 mg mL-1. This stock was then used 
in the preparation of hanging drop optimisation trays.[92]
Figure 4.6 Hanging drop crystals of LDIase mutant C171S. (A): PACT F10 C1 2:1 
(protein:reservoir) 10 mg mL-1; (B): PACT F10 + 10 mM linalool 1:1 (protein:reservoir) B1; (C): 
PACT F10 + 10 mM linalool 1:1 (protein:reservoir) C1. 
Drops producing high-quality crystals (Figure 4.6) were fished and tested, before being sent 
for data collection at Diamond Light Source. 
Linalool Dehydratase-Isomerase mutagenesis, C171S 75 
4.4. X-ray crystallography 
A crystal from PACT F10 B1 diffracted to 2.58 Å resolution, with associated data collection 
statistics described in Table 4.2. A Matthews coefficient value of 2.56 was calculated, 
suggesting a maximal probability of ten molecules in the asymmetric unit and a 52 % solvent 
content. 
Table 4.2 Data collection and refinement statistics for LDIase mutant C171S.  Numbers in 
brackets refer to data for the highest resolution shells. 
LDIase C171S 
Beamline Diamond I02 
Wavelength (Å) 0.9795 
Resolution (Å) 76.52-2.58 (2.62-2.58) 
Space Group P21
Unit cell (Å) a = 87.77; b = 109.47; c = 232.70 
α = γ = 90°; β = 99.5° 
No. of molecules in the asymmetric unit 10 
Unique reflections 135904 (6447) 
Completeness (%) 99.3 (96.0) 
Rmerge (%) 0.11 (0.74) 
Rp.i.m. 0.09 (0.64) 
Multiplicity 4.1 (3.7) 
<I/σ(I)> 8.7 (1.7) 
Overall B factor from Wilson plot (Å2) 39 
Rcryst/ Rfree (%) 18.2/21.1 
r.m.s.d 1-2 bonds (Å) 0.01 
r.m.s.d 1-3 angles (o) 1.47 
Avge main chain B (Å2) 43 
Avge side chain B (Å2) 47 
Avge water B (Å2) 39 
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The monomer of native LDIase was used to solve the structure of the mutant C171S using 
MOLREP over ten copies of the search set [2.13]. Coincidentally, the asymmetric unit was 
found to contain ten molecules constituting two dimers (Figure 4.7), whereas previously 
solved LDIase structures constituted a single pentamer. 
Figure 4.7 The X-ray crystallographic structure of the LDIase mutant C171S, consisting of a ten-
molecule asymmetric unit. (A): lateral view; (B): anterior view. 
REFMAC and COOT were used for the initial refinement, followed by iterative rounds of 
building and further refinement [2.13]. Each active site at the monomer interface showed 
red negative difference density for the side chain of residue 171, showing an occupancy error 
for cysteine which was corrected when changed to serine, thus confirming the mutation. 
The structure displayed conspicuous differences to side change positions of certain residues 
in the active site (Figure 4.8). As residue 171 no longer possessed the sulfur of cysteine, it 
could not form a disulfide bridge with Cys 180. Additionally, Trp 244 had reoriented to 
point away from the ligand binding site. It is possible that this is due to complexation with 
a ligand. 
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Figure 4.8 The LDIase mutant C171S superimposed with the previously determined geraniol-
bound structure. For the latter complex, the carbon atoms of subunits (A) and (B) are coloured 
coral and green respectively, with geraniol in grey. The carbon atoms of C171S subunits (A) and 
(B) are coloured gold and light blue respectively. The side chain of W244 is seen to move away 
from the ligand binding site in the C171S structure. 
Additional density was observed in the active site extending from Cys 180 which did not 
match the enzyme’s amino acid residues (Figure 4.9). Unfortunately, as for datasets of native 
LDIase, this occupancy could not be defined as ligand density corresponding to linalool, 
geraniol or myrcene. However, it could provide the first indication that Cys 180 acts as a 
nucleophile as proposed in the reaction mechanism, forming a covalent thioterpene 
intermediate. 
Figure 4.9 The active site of the LDIase mutant C171S showing its electron density.  The carbon 
atoms of subunits (A) and (B) are coloured gold and light blue respectively. The electron density 
corresponds to the Fo-Fc (omit) and 2Fo-Fc maps, which are shown in green and blue at levels of 
3σ and 1σ respectively. Clear electron density can be observed extending from the side-chain of 
C180, possibly indicating the low occupancy of a covalent bond to a ligand.
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R. erythropolis Linalool Dehydratase-Isomerase (ReLDIase) 
5.1. Molecular cloning 
To confer a hexahistidine tag to the N-terminus of ReLDIase, the synthesised gene required 
cloning into an appropriate vector, in this case pET-YSBLIC3C. This was accomplished by 
Ligation Independent Cloning (LIC) [2.3]. The gene of interest was amplified by PCR from 
the host pMK-RQ (kanR) plasmid as supplied by Invitrogen. The amplified gene was 
purified by gel extraction to give a yield of 121.7 ng μL-1. This was then treated with T4 
polymerase prior to annealing with linearised pET-YSBLIC3C vector (57 ng μL-1). Three 
different ratios of gene insert to vector were trialled as optimisation in the annealing step; 
1:1, 1:5, and 5:1. Each of these reactions was transformed into E. coli [2.4]. 
Colony PCR of each transformant carried out to provide an indication of success [2.3.7]. An 
agarose gel of these (Figure 5.1) suggested that all annealing reactions were successful, 
showing a band corresponding to the insert size of 1698 bp, however due to the possible 
amplification of unannealed background DNA insert this was not sufficient to confirm. 
Figure 5.1 An agarose gel of colony PCR to test the success of ReLDIase gene cloning into pET-
YSBLIC3C. Bands are visible at 1.7 kb, matching the insert size. 
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A double restriction digest using NcoI and NdeI was carried out of two transformants from 
annealing reactions of ratios 1:5 and 3:3 [2.3.8]. The agarose gel (Figure 5.2) did not show all 
expected bands, missing 904 bp, 441 bp, 354 bp, and 86 bp. Fortunately, a band 
corresponding to the expected fragment size of 5308 bp was visible, which could suggest a 
successful cloning reaction. 
Figure 5.2 A double restriction digest to test the success of ReLDIase gene cloning into pET-
YSBLIC3C. The two visible bands match an expected fragment size of 5.3 kb. 
Sequencing by GATC (T7 forward, pET-RP reverse) was used to confirm molecular cloning 
of gene into pET-YSBLIC3C. Results showed 99.7 % sequence identity due to an unresolved 
nucleotide encoding the codon for K276, though this is most likely a sequencing error. Thus, 
cloning was considered successful. 
5.2. ReLDIase expression tests 
Expression tests were carried out to investigate the effect of changing expression host, 
growth media, and induction temperature [2.7] (Figure 5.3, Figure 5.4, and Figure 5.5). 
Expression hosts tested were E. coli BL21(DE3) and E. coli Rosetta(DE3). Growth media 
tested were M9, LB, and TB. Induction temperatures tested were 16 °C, 25 °C (not including 
LB), 30 °C, and 37 °C. 
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Figure 5.3 ReLDIase expression tests in LB media. (I): BL21 expression host; (II): Rosetta 
expression host. A) denotes induction temperature; B) denotes soluble (S) or insoluble (I) 
fractions; C) denotes controls (C). 
Figure 5.4 ReLDIase expression tests in M9 media. Temperatures of induction are shown to the 
top right of each gel. A) denotes soluble (S) or insoluble (I) fractions; B) denotes controls (C); C) 
denotes expression host. 
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Figure 5.5 ReLDIase expression tests in TB media. Temperatures of induction are shown to the 
top right of each gel. A) denotes soluble (S) or insoluble (I) fractions; B) denotes controls (C); C) 
denotes expression host. 
Expression levels were high, though no protein solubility was observed to allow larger-scale 
expression for purification. 
5.3. ReLDIase expression and purification 
To test if sufficient ReLDIase may be made for purification at a larger scale of expression, 4 
L LB media was inoculated with ReLDIase in E. coli BL21(DE3) before 16 °C induction then 
pressure homogenisation. IMAC purification was performed on an ÄKTA start [2.10.1] 
(Figure 5.6). 
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Figure 5.6 Chromatogram of IMAC-purified ReLDIase using an ÄKTA start, expressed in 4 L LB 
media and lysed by pressure homogenisation. The UV absorbance is shown in blue, with the 
imidazole gradient in green. 
Figure 5.7 SDS-PAGE of selected ReLDIase fractions from IMAC purification. Lane (1): low 
molecular weight marker; lane (2): clarified cell lysate; lane (3): insoluble fraction; lane (4): IMAC-
purification wash; lanes (5-9): 5 mL fractions eluted by increasing imidazole concentration. 
Both the chromatogram and SDS-PAGE analysis (Figure 5.7) showed no soluble expression 
of the gene of interest. The short peak on the chromatogram is likely to be non-specifically 
bound background protein. An alternative strategy for soluble ReLDIase expression to 
overcome these issues was investigated. 
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5.4. ReLDI-27ase 
To improve solubility, a signal peptide was identified using SignalP, Technical University 
Denmark. 
To remove this signal peptide, a forward primer was designed starting 81 bp into the 
ReLDIase gene to remove 27 amino acid residues from the N-terminus [2.1.3]. This 
truncated protein was named ReLDI-27ase. 
For molecular cloning by LIC [2.3], this forward primer was used with the standard reverse 
primer of ReLDIase in a touchdown PCR reaction [2.3.2]. A band between 1.5-2 kb was 
excised and purified by gel extraction, followed by T4 polymerase treatment and annealing 
to linearised pET-YSBLIC3C vector (57 ng μL-1) as for ReLDIase. Reactions were 
transformed into E. coli and used for colony PCR [2.3.7]. 
Figure 5.8 An agarose gel of colony PCR to test the success of ReLDI-27ase gene cloning into 
pET-YSBLIC3C. Bands highlighted in red can be very faintly observed at ~1.7 kb, matching the 
insert size. 
The agarose gel (Figure 5.8) showed bands of the correct size, yet were too faint to be 
conclusive. A double restriction digest using NcoI and NdeI was carried out using 
transformants of the ratios 1:5 and 5:1 gene insert to vector [2.3.8] (Figure 5.9). This digest 
showed clear bands matching the expected sizes for successful cloning; 5308 bp, 904 bp, 441 
bp and 276 bp. The smallest band of 86 bp was not resolved, however due to its size this was 
expected. 
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Figure 5.9 A double restriction digest to test the success of ReLDI-27ase gene cloning into pET-
YSBLIC3C. Four visible bands match expected fragment sizes of 5.3 kb, 0.9 kb, 0.4 kb and 0.3 kb. 
5.5. ReLDI-27ase expression and purification 
ReLDI-27ase was transformed into E. coli BL21(DE3) and large-scale expression in 1 L TB 
was carried out [2.8]. Cells were lysed by sonication and purified by IMAC on an ÄKTA 
pure [2.10.1] (Figure 5.10). 
Figure 5.10 Chromatogram of IMAC-purified ReLDI-27ase using an ÄKTA pure, expressed in 1 L 
TB media and lysed by sonication. The UV absorbance is shown in blue, with the imidazole 
gradient in green. 
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Figure 5.11 SDS-PAGE of selected ReLDI-27ase fractions from IMAC purification. Lane (1): low 
molecular weight marker; lane (2): insoluble fraction; lane (3): clarified cell lysate; lane (4): 
HisTrap FF Crude column loading flow-through; lanes (5-15): 1.8 mL fractions eluted by 
increasing imidazole concentration. 
Although a peak was visualised on the chromatogram, SDS-PAGE analysis (Figure 5.11) 
showed the protein of interest was missing in fractions, yet indicated insoluble expression. 
5.6. ReLDI-27ase expression tests 
Expression tests were carried out as the next step to determine whether varying conditions 
may improve soluble expression (Figure 5.12). The same growth media and induction 
temperatures were tested as for ReLDIase. Unfortunately, soluble expression was again not 
observed. 
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Figure 5.12 ReLDI-27ase expression tests in E. coli BL21. Temperatures of induction are shown 
to the top right of each gel. A) denotes media; B) denotes soluble (S) or insoluble (I) fractions; C) 
denotes controls (C). 
5.7. Conclusions 
Although ReLDIase appeared a promising candidate for a LDIase homologue which would 
perform better under aerobic conditions, it did not demonstrate sufficient soluble 
expression for purification and crystallisation. For further investigation many strategies 
exist to potentially solve this problem, such as buffer screens during cell lysis or co-
expression of chaperones. Alternatively, a C-terminal hexahistidine tag could be used by 
changing the cloning vector. Although these strategies were not possible during the time 
frame of this work, they may provide a solution to allow structural determination of this 
enzyme. 
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Discussion 
The use of enzymes to enantioselectively add water across electron-rich carbon-carbon 
double bonds not only enriches the biocatalytic toolbox available to industry, but also allows 
for the conversion of cheap bio-derived feedstocks into fine chemicals to improve 
affordability and end our current reliance on petrochemical sources. Although enzymes exist 
which catalyse this reaction, they are limited by substrate range; oleate hydratase is cis-
specific, acetylene hydratase is oxygen sensitive, and carotenoid hydratases are cofactor 
dependent. 
Linalool Dehydratase-Isomerase (LDIase) may provide a solution to these constraints, in 
addition to providing dehydratase activity.[76] To take full advantage of this enzyme for 
industrial purposes the structure and mechanism must be understood, allowing rational 
design for a broad substrate range and maximal enantiomeric excess. 
The prior structural characterisation of LDIase has provided insight into the mechanism of 
its dehydratase and isomerase functions. However, the mechanism for enantioselective 
hydration remains elusive. Through co-crystallisation and mutagenesis studies, this work 
has provided insight into how the enzyme achieves this and provides further evidence for a 
covalent intermediate. Parallel investigation of a homologue was attempted as a step towards 
identifying a mechanistic family of hydratases. 
Co-crystallisation of LDIase aimed to yield a structure with ligand density for a linalool-
bound complex, though this was not successful. However, possible methods for overcoming 
this may exist. The reasons for oxygen-sensitivity of the enzyme are not clear; it is possible 
this may be due to the proximal cysteines 171 and 180 forming a disulfide bridge under 
oxidative conditions. Further attempts using the reducing agent dithiothreitol (DTT) in 
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purification or crystallisation could provide such a complex. In conjunction, the co-
crystallisation strategy successfully applied to the mutant may be similarly effective in this 
case. 
The aerobic homologue ReLDIase was successfully cloned into the LIC3C vector, though 
unfortunately the expressed protein was insoluble under a range of conditions. Additional 
strategies can be taken in future work to enable soluble expression of this protein. 
Mutagenesis of the LDIase cysteine residue 171 to serine allowed for structural analysis of 
its role in the catalytic mechanism. Extraneous electron density was observed in the active 
site which, although not sufficient to be a ligand-complex, could indicate a covalent bond to 
C180. H129 is also located proximally to this density, further suggesting its catalytic 
importance. Further mutagenesis of C171 to an alanine could shed further light on this 
mechanism by removing the side chain altogether. 
Overall, this work has demonstrated the difficult expression of a homologue ReLDIase, 
formed a reliable strategy for crystallisation of the protein LDIase, and provided further 
evidence through mutagenesis for the formation of a covalent intermediate in its 
mechanism. A pathway for subsequent experiments will allow for a complete mechanistic 
understanding of this novel hydration mechanism and its future rational design for 
industrial applications. 
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APS  Ammonium persulfate 
CV  Column volumes 
DMSO  Dimethyl sulfoxide 
IMAC  Immobilised Metal Affinity Chromatography 
IPTG  Isopropyl β-D-thiogalactopyranoside 
LC-MS Liquid Chromatography-tandem Mass Spectrometry 
LIC  Ligation Independent Cloning 
LDIase  Linalool Dehydratase-Isomerase 
M9  Minimal media 9 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase Chain Reaction 
ReLDIase  Rhodococcus erythropolis Linalool Dehydratase-Isomerase 
ReLDI-27ase  R. erythropolis Linalool Dehydratase-Isomerase, sans signal peptide 
SDS  Sodium dodecyl sulfate 
SEC  Size Exclusion Chromatography 
TAE  Tris-acetate-EDTA 
TEMED  Tetramethylethylenediamine 
Tris  Tris(hydroxymethyl)aminomethane 
UPW  Type I ultrapure water (> 18 MΩ·cm) 
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